Could not find the file: /1291/1/Oncology Fact Sheet Nr.35_Update.pdf
The file you are trying to access may be related to this item:
Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.
If you reached this page by following a link within the repository, please contact the Repository of AIHTA GmbH administration. Otherwise, please check that you have typed the URL in correctly, or contact the person or site that supplied you with this URL.